Cargando…
Guselkumab for the treatment of psoriasis – evidence to date
Psoriasis is a chronic, immune-mediated, inflammatory, and debilitating skin disease with significant impact on patients’ quality of life. Its pathogenesis is complex and not yet fully understood. However, the IL-23/IL-17 axis is currently considered the main pathogenic pathway in psoriasis. Guselku...
Autores principales: | Nogueira, Miguel, Torres, Tiago |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioExcel Publishing Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668503/ https://www.ncbi.nlm.nih.gov/pubmed/31391856 http://dx.doi.org/10.7573/dic.212594 |
Ejemplares similares
-
Management of psoriasis in pregnancy – a review of the evidence to date
por: Ferreira, Clara, et al.
Publicado: (2020) -
Guselkumab for plaque psoriasis
Publicado: (2019) -
Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
por: Machado, Álvaro, et al.
Publicado: (2018) -
Targeting p19 as a treatment option for psoriasis: an evidence-based review of guselkumab
por: Wechter, Todd, et al.
Publicado: (2018) -
Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials
por: Nakamura, Mio, et al.
Publicado: (2017)